- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04062318
Beta Events and Sensory Perception
The Causal Role of Neocortical Beta Events in Human Sensory Perception
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prior studies have shown that high power low-frequency brain rhythms in the alpha (8-14) and beta (15-29 Hz) bands in primary somatosensory cortex (SI) are associated with a decreased probability of perceiving tactile stimuli at perceptual threshold, and can be modulated with attention. Furthermore, high power beta activity in SI emerges as brief "events" (<150ms) in un-averaged data, the rate and timing of which underlie the attentional and perceptual effects associated with high beta power.
In this study, human electroencephalography (EEG) and a non-painful tactile detection task are used to assess if TMS that is hypothesized to mimic endogenous beta-frequency events impact touch perception in a similar manner.
The TMS-EEG components of this study will use a within-subjects crossover design. In initial study sessions, all participants will have an MRI. In subsequent study sessions, participants will complete a tactile detection task while EEG data is recorded concurrent with online active, active control or sham control TMS. Analyses will focus on comparing detection probabilities of tactile stimuli presented at perceptual threshold and tactile evoked response potential waveforms between trials with and without concurrent TMS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Brown University, Carney Institute for Brain Science Human Testing Space (HuTS)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to provide informed consent/assent
- Age: 18-65 years
- English fluency: participants must be able to understand screening questionnaires and task instructions spoken/written in English.
- Right handed: to reduce heterogeneity related to hand dominance, since our task involves touch perception on the hand, and examination of neural correlates in lateralized brain regions.
Exclusion Criteria:
- History of fainting spells of unknown or undetermined etiology that might constitute seizures
- History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy
- Any progressive (e.g., neurodegenerative) neurological disorder
- Chronic medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
- Metal implants (excluding dental fillings)
- Pacemaker
- Implanted medication pump or cochlear implant
- Vagal nerve stimulator
- Deep brain stimulator
- TENS unit (unless removed completely for the study)
- Ventriculo-peritoneal shunt
- Signs of increased intracranial pressure
- Intracranial lesion
- History of head injury resulting in prolonged loss of consciousness
- Pregnancy
- Participants who have received prior TMS for medical treatment purposes.
- Intellectual Disability or autism spectrum disorder (ASD)
- Active psychosis, diagnosis of unipolar depression or bipolar disorder, active severe substance use disorders (within the last month), or active suicidal intent or ideations.
- Conditions that may result in the inability to effectively carry out the tactile detection task, including loss of feeling, neuropathy or nerve damage in the hands or feet, chronic pain or fibromyalgia, and pain due to cancer, infection or arthritis.
- If the participant is actively taking any of the medications that increase risk from TMS as indicated below, of if they have ingested any alcohol or any other drugs of abuse (see https://www.drugabuse.gov/drugs-abuse) on the day of the study session (prior to the session).
Contraindicated medications:
alcohol Amitriptyline Amphetamines ampicillin Anticholinergics Antihistamines aripiprazole BCNU **bupropion** cephalosporins chlorambucil chloroquine Chlorpromazine citalopram Clozapine Cocaine cyclosporine cytosine arabinoside Doxepine duloxetine fluoxetine fluphenazine fluvoxamine Foscarnet gamma-hydroxybutyrate (GHB) Ganciclovir haloperidol imipenem Imipramine isoniazid ketamine levofloxacin Lithium Maprotiline MDMA (ecstasy) mefloquine methotrexate metronidazole mianserin mirtazapine Nortriptyline olanzapine paroxetine penicillin phencyclidine (PCP, angel's dust) pimozide quetiapine reboxetine risperidone Ritonavir **Sertraline** Sympathomimetic theophylline venlafaxine vincristine ziprasidone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active SI-Hand TMS vs. Active Control TMS
Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection.
EEG is recorded and TMS is applied concurrently during the task.
In one study session, active TMS is applied over the hand region of primary somatosensory cortex (SI-Hand).
In another study session, active TMS is applied over a control brain region, in a more superior and lateral location within SI.
|
Single pulses of TMS will be delivered using an active coil.
One pulse will be delivered per trial (at least 5 seconds apart) "online" (during the tactile detection task), at 80% active motor threshold.
TMS will target the hand area of primary somatosensory cortex (SI-Hand).
Single pulses of TMS will be delivered using an active coil.
One pulse will be delivered per trial (at least 5 seconds apart) "online" (during the tactile detection task), at 80% active motor threshold.
TMS will target a control brain region, in a more superior and lateral location within SI.
This control condition is intended to mimic the peripheral (e.g.
cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
|
|
Experimental: Active SI-Hand TMS vs. Sham SI-Hand TMS
Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection.
EEG is recorded and TMS is applied concurrently during the task.
In one study session, active TMS is applied over the hand region of primary somatosensory cortex (SI-Hand).
In another study session, sham TMS is applied over the same target location (SI-Hand)
|
Single pulses of TMS will be delivered using an active coil.
One pulse will be delivered per trial (at least 5 seconds apart) "online" (during the tactile detection task), at 80% active motor threshold.
TMS will target the hand area of primary somatosensory cortex (SI-Hand).
Single pulses of TMS will be delivered using a sham coil.
One pulse will be delivered per trial (at least 5 seconds apart) "online" (during the tactile detection task), at 80% active motor threshold.
TMS will target the hand area of primary somatosensory cortex (SI-Hand).
This control condition is intended to mimic the peripheral (e.g.
cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Threshold-Level Tactile Detection Hit Rate
Time Frame: Tactile detection was assessed between TMS and no TMS trials continuously during the TMS interventions - during the Active SI TMS session, and during either the Active Control TMS or Sham Control TMS session. The sessions were at least 1 week apart.
|
Participants receive one or zero tactile stimuli per trial and report detection or non-detection using a button press.
Tactile stimuli are delivered at participants' individual perceptual threshold level (perceived roughly half the time).
On a given trial, TMS may also be delivered 100 msec before the tap ('TMS100'), 25 msec after the tap ('TMS25'), or not at all ('TMS Null'), each for an equal number of trials.
The 'hit rate' is defined as the number of trials with correctly detected tactile stimuli divided by the total number of trials on which a tactile stimulus was presented.
|
Tactile detection was assessed between TMS and no TMS trials continuously during the TMS interventions - during the Active SI TMS session, and during either the Active Control TMS or Sham Control TMS session. The sessions were at least 1 week apart.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EEG Tactile Evoked Response Potential (ERP)
Time Frame: EEG measures were assessed between TMS and no TMS trials continuously during the TMS interventions - during the Active SI TMS session, and during either the Active Control TMS or Sham Control TMS session. The sessions were at least 1 week apart.
|
Participants receive one tactile stimulus per trial concurrent with EEG recording.
The EEG-measured ERP immediately following each tactile stimulus is assessed and compared across conditions, with and without TMS at different latencies.
'TMS null' refers to trials in which no TMS was delivered, 'TMS100' refers to trials in which TMS was delivered 100 msec before the tactile stimulus, and 'TMS25' refers to trials in which TMS was delivered 25 msec after the tactile stimulus.
'Hit trials' are trials in which the tactile stimulus was delivered and corrected detected, and 'miss trials' are trials in which the tactile stimulus was delivered but incorrectly not detected.
The outcome measure calculated here represents a time window between 78-161 msec after the tactile stimulus, where we expected to see a significant difference in signal amplitude between hit and miss trials based on prior publications.
|
EEG measures were assessed between TMS and no TMS trials continuously during the TMS interventions - during the Active SI TMS session, and during either the Active Control TMS or Sham Control TMS session. The sessions were at least 1 week apart.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephanie R Jones, PhD, Brown University
Publications and helpful links
General Publications
- Jones SR, Kerr CE, Wan Q, Pritchett DL, Hamalainen M, Moore CI. Cued spatial attention drives functionally relevant modulation of the mu rhythm in primary somatosensory cortex. J Neurosci. 2010 Oct 13;30(41):13760-5. doi: 10.1523/JNEUROSCI.2969-10.2010.
- Sherman MA, Lee S, Law R, Haegens S, Thorn CA, Hamalainen MS, Moore CI, Jones SR. Neural mechanisms of transient neocortical beta rhythms: Converging evidence from humans, computational modeling, monkeys, and mice. Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4885-94. doi: 10.1073/pnas.1604135113. Epub 2016 Jul 28.
- Shin H, Law R, Tsutsui S, Moore CI, Jones SR. The rate of transient beta frequency events predicts behavior across tasks and species. Elife. 2017 Nov 6;6:e29086. doi: 10.7554/eLife.29086.
- Jones SR, Pritchett DL, Stufflebeam SM, Hamalainen M, Moore CI. Neural correlates of tactile detection: a combined magnetoencephalography and biophysically based computational modeling study. J Neurosci. 2007 Oct 3;27(40):10751-64. doi: 10.1523/JNEUROSCI.0482-07.2007.
- Jones SR, Pritchett DL, Sikora MA, Stufflebeam SM, Hamalainen M, Moore CI. Quantitative analysis and biophysically realistic neural modeling of the MEG mu rhythm: rhythmogenesis and modulation of sensory-evoked responses. J Neurophysiol. 2009 Dec;102(6):3554-72. doi: 10.1152/jn.00535.2009. Epub 2009 Oct 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1902002327
- P20GM103645 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta Rhythm
-
Riphah International UniversityRecruiting
-
Brigham and Women's HospitalNSBRICompletedCircadian RhythmUnited States
-
Brigham and Women's HospitalNational Center for Complementary and Integrative Health (NCCIH)Completed
-
University of AarhusRecruitingCircadian Rhythm | Time PerceptionDenmark
-
University of Alabama at BirminghamAmerican Heart AssociationCompletedBlood Pressure | Circadian RhythmUnited States
-
Università degli Studi di BresciaCompletedSleep Phase Rhythm DisturbanceItaly
-
Samsung Medical CenterCompletedCircadian Rhythm Phase Shift
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
University Hospital, Clermont-FerrandNot yet recruitingIncidence of Junctional RhythmFrance
Clinical Trials on Online Active SI-Hand TMS
-
Auburn UniversityNational Institute on Drug Abuse (NIDA); Society of Addiction PsychologyRecruiting
-
NYU Langone HealthWithdrawn
-
Centre Hospitalier St AnneRecruitingTreatment Resistant SchizophreniaFrance
-
University of MinnesotaCompletedTourette's Syndrome | Chronic Motor Tic Disorder | Chronic Vocal Tic DisorderUnited States
-
University of PennsylvaniaNot yet recruiting
-
Subha SubramanianRecruitingMajor Depressive Disorder (MDD)United States
-
Changping LaboratoryRecruitingDepression | Major Depressive Disorder | Severe DepressionChina
-
University of PennsylvaniaNot yet recruiting
-
Ankara Etlik City HospitalRecruitingNeuropathic Pain | Spinal Cord InjuryTurkey (Türkiye)